Login to Your Account



Clinic Roundup


Wednesday, August 24, 2011
• PharmaNeuroBoost NV, of Alken, Belgium, received clearance from a U.S.-based institutional review board to begin a Phase III trial with PNB01 for major depression. PNB01 is a combination of the antidepressant citalopram and a low dose of the neuroleptic agent pipamperone.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription